X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, Eikon received an exclusive license from Impact to co-develop, register, manufacture, and commercialize IMP1734 and other PARP1 selective inhibitors globally, excluding Greater China.
Lead Product(s): IMP1734
Therapeutic Area: Oncology Product Name: IMP1734
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Eikon Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 01, 2023
Details:
IMP4927 (senaparib) is a PARP inhibitor, being investigated as monotherapy maintenance treatment following first-line platinum-based chemotherapy in patients with FIGO stage III/IV ovarian cancer who have achieved complete response or partial response.
Lead Product(s): Senaparib
Therapeutic Area: Oncology Product Name: IMP4927
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Shanghai Junshi Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2023
Details:
The preliminary clinical results for a phase I b/II study investigating the PARP inhibitor IMP4297 having Senaparib in combination with temozolomide (TMZ) for the treatment of advanced solid tumors.
Lead Product(s): Senaparib,Temozolomide
Therapeutic Area: Oncology Product Name: IMP4297
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2022
Details:
Proceeds will be used to accelerate the development of its synthetic lethality programs, including IMP4297, which are showing best-in-class potential. The company already has three synthetic lethality compounds in the clinical stage.
Lead Product(s): Senaparib
Therapeutic Area: Oncology Product Name: IMP4297
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dingxin Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Series D Financing March 14, 2022
Details:
Under the collaboration, Burning Rock will provide the testing services in connection with IMPACT Therapeutics’ development of its ATR inhibitor IMP9064, with worldwide intellectual property rights.
Lead Product(s): IMP9064,Senaparib
Therapeutic Area: Oncology Product Name: IMP9064
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Burning Rock Dx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 04, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
